Search

everythinglearnresearchcommunity

for

Search:↓

Hair loss treatments, specifically 5AR inhibitors, can impact neurosteroids and sexual health. The effects of topical fin/dut on tissue-specific DHT levels are unclear.

The conversation discusses using pumpkin seed oil and rosemary oil for hair thinning, with skepticism about their effectiveness compared to pharmaceutical options like finasteride and minoxidil. Some users suggest trying natural treatments, while others emphasize the proven success of pharmaceuticals.

The conversation discusses why some people who use hard drugs have great hair, with various opinions suggesting genetics and higher estrogen levels as possible reasons. Specific treatments like Minoxidil, finasteride, and RU58841 are not mentioned.

SCUBE3 and Amplifica's progress in hair loss treatment is being discussed, with inquiries about their current status and clinical trials. No specific updates or new information are provided in the conversation.

Hmi115, a prolactin receptor blocker, showed promise for hair growth, but results from Phase 2 trials have not been published. ABS-201, an AI-based analog, is expected to begin trials in December 2025, while commercialization of treatments like PP-405 is anticipated around 2027.

The conversation discusses GT20029 as a potential hair loss treatment that could act like a cure by targeting androgen receptors in scalp hair follicles. Specific treatments mentioned include GT20029, with a user expressing hope that it could make male pattern baldness obsolete.

The user experienced side effects from using 1% finasteride and 2% minoxidil, including dermatitis, erectile dysfunction, and heart palpitations. They switched to using 2000mg pumpkin seed oil, saw palmetto capsules, and applying pumpkin seed oil and rosemary oil twice a week, seeking feedback on results.

The conversation discusses the potential market release of a hair loss treatment called GT20029 by Anageninc, with users expressing interest and discussing the importance of safety and effectiveness. Some users plan to contact Anageninc to show demand for the product.

The conversation is about the effectiveness of peptides for hair loss and the user considering using GHK-Cu, CJC-1295, and BPC-157 for treatment.

Pelage Pharmaceuticals is developing PP405, a topical treatment for hair growth, currently in Phase 2a trials. There is skepticism about the company's claims, and no fast-tracking approval timeline has been detailed.

The user is using a topical solution containing 1% finasteride and 5% minoxidil for hair loss, with water, glycerin, and PEG-40 hydrogenated castor oil as carrier agents. They are questioning if these ingredients are effective carriers after using the solution for three months.

Rosemary extract showed high inhibitory activity against DHT, similar to finasteride and dutasteride, but the conversation includes skepticism about its effectiveness in humans since the study was done on mice and rosemary oil is often considered ineffective based on personal experiences. Some suggest trying rosemary oil alongside other treatments, while others emphasize the difference between the extract used in the study and the oil.

Hair loss discussion includes treatments like hinoki tree oil and procyanidin b2. Experiences and effectiveness of these treatments are shared.

The conversation is about sourcing gray market compounds, gt20029 and pp405, for hair loss treatment. The user is interested in these compounds despite their unproven status and potential risks.

User experienced hair thickening with pyri but also side effects like reduced sex drive. Stopping pyri and returning to CB restored sex drive, suggesting pyri may go systemic or be incorrectly formulated.

Topical melatonin, caffeine, and adenosine have shown impressive results in increasing hair density by 55% in 8 weeks, according to a Medium article.

Dutasteride is associated with increased blood glucose, HbA1c, LDL cholesterol, and liver enzyme activity, potentially leading to diabetes, NAFLD, and liver metabolism changes. The conversation highlights concerns about these adverse effects and calls for more studies, including on finasteride.

Pumpkin seed oil showed a 40% increase in hair count, but its effectiveness is questioned due to other ingredients in the supplement. Users discuss its potential compared to finasteride, with some expressing skepticism and others showing interest.

The user is using 0.1% dutasteride, 1% minoxidil with 2% procapil and 0.005% caffeine in the morning, and 1% minoxidil with 2% procapil and 0.01% tretinoin at night. They are concerned about the solution vehicle's effectiveness in preventing systemic absorption and ensuring the products stay around the hair follicles.

A user plans to experiment with creating new hair follicles using methods like derma rolling, applying lithium chloride, tannic acid, and various other substances including caffeine, ketoconazole, and raspberry ketones. They also consider using anti-inflammatories, immunosuppressants, and DHT inhibitors to potentially improve results.

PP405 is a promising molecule that may reactivate dormant hair follicles, potentially offering a new treatment for hair loss. It is in phase 2 trials, with possible availability between 2027 and 2030.

Mixing RU58841 with cetosomal minoxidil is discussed due to scalp irritation from ethanol PG vehicles. A mixture of the two turned bright pink when left to dry.

Corticosterone inhibits GAS6, affecting hair follicle stem-cell activity, with potential implications for stress-related hair loss. Ashwagandha and Vitamin K are suggested for reducing cortisol, but their effectiveness is debated.

The conversation discusses using cetirizine (Zyrtec) topically to relieve scalp itch associated with hair loss and suggests it may also benefit androgenetic alopecia (AGA). One person found relief from scalp itch after three months on finasteride, noting the itch was linked to areas where hair was lost.

Pyrilutamide, a new hair loss product with the potential to be more effective than RU58841 and safer than CB, but expensive.

A topical treatment called 1961, containing multiple products, is discussed for its compatibility with finasteride. It is suggested that 1961 does not negatively affect finasteride's effectiveness and may even enhance its absorption.

Amplifica is testing a compound called AMP-303 for hair loss, but it's not Scube3 or osteopontin. The timing for the results from the clinical trial is unknown.

Minoxidil and caffeine are discussed for hair loss treatment. The user questions the logic of combining them due to their opposing effects on adenosine receptors.

Breezula (clascoterone) is expected to be available by late 2026, showing good long-term results with minimal side effects. KX-826 (pyrilutamide) acts faster but is still in earlier development stages.

Rosemary oil can smell like camphor and is considered okay for hair use. The user bought a large bottle from a wholesaler to save costs.